These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35116079)

  • 21. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How do patients with inflammatory bowel disease want their biological therapy administered?
    Allen PB; Lindsay H; Tham TC
    BMC Gastroenterol; 2010 Jan; 10():1. PubMed ID: 20064220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
    Wolf D; D'Haens G; Sandborn WJ; Colombel JF; Van Assche G; Robinson AM; Lazar A; Zhou Q; Petersson J; Thakkar RB
    Aliment Pharmacol Ther; 2014 Sep; 40(5):486-97. PubMed ID: 25041859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
    Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
    Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
    Panaccione R; Colombel JF; Sandborn WJ; Rutgeerts P; D'Haens GR; Robinson AM; Chao J; Mulani PM; Pollack PF
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1296-309. PubMed ID: 20298496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
    Viola F; Civitelli F; Di Nardo G; Barbato MB; Borrelli O; Oliva S; Conte F; Cucchiara S
    Am J Gastroenterol; 2009 Oct; 104(10):2566-71. PubMed ID: 19550415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease.
    Jasurda JS; McCabe RP; Vaughn BP
    Ther Drug Monit; 2021 Oct; 43(5):645-651. PubMed ID: 33346627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire.
    Bodger K; Ormerod C; Shackcloth D; Harrison M;
    Gut; 2014 Jul; 63(7):1092-102. PubMed ID: 24107590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease.
    König HH; Ulshöfer A; Gregor M; von Tirpitz C; Reinshagen M; Adler G; Leidl R
    Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1205-15. PubMed ID: 12439115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
    Scheinfeld N; Sundaram M; Teixeira H; Gu Y; Okun M
    Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
    Luis M; Pacheco-Tena C; Cazarín-Barrientos J; Lino-Pérez L; Goycochea MV; Vazquez-Mellado J; Burgos-Vargas R
    Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial.
    Kivitz A; Cohen S; Dowd JE; Edwards W; Thakker S; Wellborne FR; Renz CL; Segurado OG
    Clin Ther; 2006 Oct; 28(10):1619-29. PubMed ID: 17157117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perceived Quality of Care is Associated with Disease Activity, Quality of Life, Work Productivity, and Gender, but not Disease Phenotype: A Prospective Study in a High-volume IBD Centre.
    Gonczi L; Kurti Z; Verdon C; Reinglas J; Kohen R; Morin I; Chavez K; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
    J Crohns Colitis; 2019 Sep; 13(9):1138-1147. PubMed ID: 30793162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis.
    Narula N; Wong ECL; AlRamdan R; Bualbanat H; Marshall JK; Steinhart AH; Greener T; Silverberg MS
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2803-2812. PubMed ID: 34020510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice.
    van den Reek JM; van Lümig PP; Kievit W; Zweegers J; van de Kerkhof PC; Seyger MM; de Jong EM
    J Dermatolog Treat; 2013 Oct; 24(5):361-8. PubMed ID: 23194389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.